Literature DB >> 25319740

ST Elevation Myocardial Infarction Mortality Among Patients With Liver Cirrhosis: A Nationwide Analysis Across a Decade.

Marwan S Abougergi1, Raffi Karagozian, Norman D Grace, John R Saltzman, Amir A Qamar.   

Abstract

BACKGROUND: Mortality from ST elevation myocardial infarction (STEMI) is decreasing nationwide, but no report to date examined STEMI mortality among patients with cirrhosis. GOALS: Determine mortality rates and investigate possible disparities in cardiovascular interventions for patients with and without cirrhosis admitted with STEMI across a decade using a national database. STUDY: We included all urgent/emergent admissions with STEMI to acute care hospitals across the United States in 1999 and 2009. Exclusion criteria were age less than 18 years or prior liver transplantation. Confounders were accounted for using multivariable regression analyses.
RESULTS: A total of 325,857 and 182,491 patients with STEMI were included in 1999 and 2009, respectively, 741 and 541 of whom had cirrhosis, respectively. In-hospital mortality rate was 31% and 11% for patients with and without cirrhosis in 1999, and 17% and 9% in 2009. The adjusted mortality odds ratio was 2.54 (1.52 to 4.24) in 1999 and 1.45 (0.73 to 2.86) in 2009. Stent placement rate was 11% and 26% for patients with and without cirrhosis in 1999, and increased to 47% and 61% in 2009, respectively. Thrombolytic medication injection rate was 3% and 10% for patients with and without cirrhosis in 1999, and 0% and 2% in 2009, respectively. Coronary artery bypass graft surgery rate was 3% and 9% for patients with and without cirrhosis in 1999, and was 6% and 7% in 2009, respectively.
CONCLUSIONS: STEMI mortality in patients with cirrhosis is higher compared with patients without cirrhosis. However, this mortality difference declined from 1999 to 2009, likely because of higher coronary artery stent utilization for patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25319740     DOI: 10.1097/MCG.0000000000000251

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

Review 1.  Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis.

Authors:  Taha Ahmed; Alla Y Grigorian; Adrian W Messerli
Journal:  Am J Cardiovasc Drugs       Date:  2021-05-29       Impact factor: 3.571

2.  Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017).

Authors:  Alaa Badawi; Giancarlo Di Giuseppe; Paul Arora
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

Review 3.  Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury.

Authors:  Irina Gîrleanu; Anca Trifan; Laura Huiban; Cristina Muzîca; Oana Cristina Petrea; Ana Maria Sîngeap; Camelia Cojocariu; Stefan Chiriac; Tudor Cuciureanu; Irina Iuliana Costache; Carol Stanciu
Journal:  Life (Basel)       Date:  2022-07-12

4.  Impact of hepatitis C virus infection on long-term mortality after acute myocardial infarction: a nationwide population-based, propensity-matched cohort study in Taiwan.

Authors:  Shu-Hung Kuo; Wang-Ting Hung; Pei-Ling Tang; Wei-Chun Huang; Jin-Shiou Yang; Hsiao-Chin Lin; Guang-Yuan Mar; Hong-Tai Chang; Chun-Peng Liu
Journal:  BMJ Open       Date:  2018-01-26       Impact factor: 2.692

5.  Selection of β-Blocker in Patients With Cirrhosis and Acute Myocardial Infarction: A 13-Year Nationwide Population-Based Study in Asia.

Authors:  Victor Chien-Chia Wu; Shao-Wei Chen; Pei-Chi Ting; Chih-Hsiang Chang; Michael Wu; Ming-Shyan Lin; Ming-Jer Hsieh; Chao-Yung Wang; Shang-Hung Chang; Kuo-Chun Hung; I-Chang Hsieh; Pao-Hsien Chu; Cheng-Shyong Wu; Yu-Sheng Lin
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

6.  Nationwide cohort study of outcomes of acute myocardial infarction in patients with liver cirrhosis: A nationwide cohort study.

Authors:  Victor Chien-Chia Wu; Shao-Wei Chen; An-Hsun Chou; Michael Wu; Pei-Chi Ting; Shang-Hung Chang; Chao-Yung Wang; Ming-Shyan Lin; Kuo-Chun Hung; I-Chang Hsieh; Pao-Hsien Chu; Cheng-Shyong Wu; Yu-Sheng Lin
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.